Literature DB >> 10399889

Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.

L S Parnes1, A H Sun, D J Freeman.   

Abstract

OBJECTIVE: Autoimmune disease (e.g., Cogan syndrome) and other inflammatory inner ear diseases may ravage the labyrinth if not treated aggressively with antiinflammatory medication. Corticosteroids are the mainstay of treatment, yet, partly because of the existence of the blood-labyrinthine barrier, the ideal drug, dose, and route of administration are currently unknown. STUDY
DESIGN: In the present study, we established cochlear fluid pharmacokinetic profiles of hydrocortisone, methylprednisolone, and dexamethasone in the guinea pig following oral, intravenous, and topical (intratympanic) administration. High-performance liquid chromatography was used to determine the drug concentrations, and comparisons were made with simultaneous pharmacokinetic profiles from blood and cerebrospinal fluid.
RESULTS: Our findings demonstrated a much higher penetration of all three drugs into the cochlear fluids following topical application as compared with systemic administration, with methylprednisolone showing the best profile. DISCUSSION: The results suggested that intratympanic administration of corticosteroids might be more efficacious while avoiding high blood levels and therefore the deleterious side effects of systemic use. CLINICAL APPLICATION: Thirty-seven patients with various inner ear disorders causing sensorineural hearing loss were subsequently treated using intratympanic corticosteroids, 20 with dexamethasone, and 17 with methlyprednisolone. Patients with immune-mediated hearing losses showed the best results, with notable improvement also seen in several cases of a "sudden deafness." No benefit was seen in patients with cochlear hydrops or those with sudden deterioration of a preexisting hearing loss. Three patients developed a transient otitis media related to the treatments, easily controlled with antibiotics. There were no cases of treatment-induced hearing loss and no permanent tympanic membrane perforations.
CONCLUSIONS: Overall injection of intratympanic corticosteroids for the treatment of hearing loss in inner ear disorders appears to be both safe and highly effective for certain disorders. The concept of this technique is supported by animal experimental data. The findings from the present study warrant further clinical application and experimental investigation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399889     DOI: 10.1097/00005537-199907001-00001

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  114 in total

1.  Early combination treatment with intratympanic steroid injection in severe to profound sudden sensorineural hearing loss improves speech discrimination performance.

Authors:  Young Ho Kim; Kyung Tae Park; Byung Yoon Choi; Min Hyun Park; Jun Ho Lee; Seung-Ha Oh; Sun O Chang
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-08       Impact factor: 2.503

2.  Intratympanic steroids in severe to profound sudden sensorineural hearing loss as salvage treatment.

Authors:  Jong Dae Lee; Moo Kyun Park; Chi-Kyou Lee; Kye Hoon Park; Byung Don Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-09-17       Impact factor: 3.372

3.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

4.  Current aspects of hearing loss from occupational and leisure noise.

Authors:  S Plontke; H-P Zenner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

5.  [Intratympanic glucocorticoid therapy of sudden hearing loss].

Authors:  S K Plontke
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

Review 6.  The role of glucocorticoids for spiral ganglion neuron survival.

Authors:  David Xu Jin; Zhaoyu Lin; Debin Lei; Jianxin Bao
Journal:  Brain Res       Date:  2009-02-21       Impact factor: 3.252

7.  Transtympanic corticoid therapy for acute profound hearing loss.

Authors:  Jürgen Lautermann; Holger Sudhoff; Rüdiger Junker
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-03       Impact factor: 2.503

8.  Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy.

Authors:  Haralampos Gouveris; Oksana Selivanova; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-04-29       Impact factor: 2.503

9.  Role of mannitol in reducing postischemic changes in distortion-product otoacoustic emissions (DPOAEs): a rabbit model.

Authors:  Krzysztof Morawski; Fred F Telischi; Faisal Merchant; Lidet W Abiy; Grazyna Lisowska; Grzegorz Namyslowski
Journal:  Laryngoscope       Date:  2003-09       Impact factor: 3.325

Review 10.  Pharmacokinetic principles in the inner ear: Influence of drug properties on intratympanic applications.

Authors:  Alec N Salt; Stefan K Plontke
Journal:  Hear Res       Date:  2018-03-11       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.